p16 immunohistochemistry as an alternative marker to distinguish atypical lipomatous tumor from deep-seated lipoma

Applied Immunohistochemistry and Molecular Morphology

Volumn 17, Issue 1, 2009, Pages 51-56

  He, Mai ^a,b   Aisner, Seena ^a   Benevenia, Joseph ^a   Patterson, Francis ^a   Aviv, Hana ^a   Hameed, Meera ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Immunohistochemistry; Lipoma; Liposarcoma; MDM2; p16

Indexed keywords

PROTEIN MDM2; PROTEIN P16; TUMOR MARKER; CYCLIN DEPENDENT KINASE INHIBITOR 2A; MDM2 PROTEIN, HUMAN; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ATYPICAL LIPOMATOUS TUMOR; BENIGN TUMOR; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; DEEP SEATED LIPOMA; DIFFERENTIAL DIAGNOSIS; FEMALE; HIBERNOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIPOBLASTOMA; LIPOMA; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; CHEMISTRY; LIPOSARCOMA; PATHOLOGY; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

CYCLIN-DEPENDENT KINASE INHIBITOR P16; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOHISTOCHEMISTRY; LIPOMA; LIPOSARCOMA; NEOPLASM PROTEINS; NEOPLASMS, ADIPOSE TISSUE; PROTO-ONCOGENE PROTEINS C-MDM2; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 58749091695     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e3181719223     Document Type: Article

References (18)

1. Enterline HT, Culberson JD, Rochlin DB, et al. Liposarcoma. A clinical and pathological study of 53 cases. Cancer. 1960;13:932-950.
2. Dal Cin P, Kools P, Sciot R, et al. Cytogenetic and fluorescence in situ hybridization investigation of ring chromosomes characterizing a specific pathologic subgroup of adipose tissue tumors. Cancer Genet Cytogenet. 1993;68:85-90. (Pubitemid 23238697)
3. Pilotti S, Della Torre G, Lavarino C, et al. Molecular abnormalities in liposarcoma: role of MDM2 and CDK4-containing amplicons at 12q13-22. J Pathol. 1998;185:188-190. (Pubitemid 28270932)
4. Dray M, Russell P, Dalrymple C, et al. p16(INK4a) as a complementary marker of high-grade intraepithelial lesions of the uterine cervix. I: experience with squamous lesions in 189 consecutive cervical biopsies. Pathology. 2005;37:112-124.
5. Agoff SN, Lin P, Morihara J, et al. p16(INK4a) expression correlates with degree of cervical neoplasia: a comparison with Ki- 67 expression and detection of high-risk HPV types. Mod Pathol. 2003;16:665-673.
6. Negri G, Egarter-Vigl E, Kasal A, et al. p16INK4a is a useful marker for the diagnosis of adenocarcinoma of the cervix uteri and its precursors: an immunohistochemical study with immunocytochemical correlations. Am J Surg Pathol. 2003;27:187-193. (Pubitemid 36152227)
7. Yoo J, Park SY, Kang SJ, et al. Altered expression of G1 regulatory proteins in human soft tissue sarcomas. Arch Pathol Lab Med. 2002;126:567-573. (Pubitemid 34477952)
8. Binh MB, Sastre-Garau X, Guillou L, et al. MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data. Am J Surg Pathol. 2005;29:1340-1347. (Pubitemid 41368770)
9. Kalof A, Cooper K. Does immunohistochemistry help in distinguishing atypical lipomatous tumors from benign lipoma? Adv Anat Pathol. 2007;14:231.
10. Nakayama T, Toguchida J, Wadayama B, et al. MDM2 gene amplification in bone and soft-tissue tumors: association with tumor progression in differentiated adipose-tissue tumors. Int J Cancer. 1995;64:342-346.
11. Pilotti S, Della Torre G, Mezzelani A, et al. The expression of MDM2/CDK4 gene product in the differential diagnosis of well differentiated liposarcoma and large deep-seated lipoma. Br J Cancer. 2000;82:1271-1275. (Pubitemid 30145344)
12. Binh MB, Garau XS, Guillou L, et al. Reproducibility of MDM2 and CDK4 staining in soft tissue tumors. Am J Clin Pathol. 2006;125:693-697.
13. Sirvent N, Coindre JM, Maire G, et al. Detection of MDM2-CDK4 amplification by fluorescence in situ hybridization in 200 paraffinembedded tumor samples: utility in diagnosing adipocytic lesions and comparison with immunohistochemistry and real-time PCR. Am J Surg Pathol. 2007;31:1476-1489. (Pubitemid 47482460)
14. Sabah M, Cummins R, Leader M, et al. Immunoreactivity of p53, Mdm2, p21(WAF1/CIP1) Bcl-2, and Bax in soft tissue sarcomas: correlation with histologic grade. Appl Immunohistochem Mol Morphol. 2007;15:64-69.
15. Yao J, Pollock RE, Lang A, et al. Infrequent mutation of the p16/MTS1 gene and overexpression of cyclin-dependent kinase 4 in human primary soft-tissue sarcoma. Clin Cancer Res. 1998; 4:1065-1070. (Pubitemid 28183410)
16. Sabah M, Cummins R, Leader M, et al. Aberrant expression of the Rb pathway proteins in soft tissue sarcomas. Appl Immunohistochem Mol Morphol. 2006;14:397-403. (Pubitemid 44813699)
17. Cohen JA, Geradts J. Loss of RB and MTS1/CDKN2 (p16) expression in human sarcomas. Hum Pathol. 1997;28:893-898.
18. Singer S, Socci ND, Ambrosini G, et al. Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. Cancer Res. 2007;67:6626-6636.